

# **Infinite Computer Solutions**

# High client concentration comes to haunt

#### November 9, 2011


Reco	Previous Reco
Buy	Buy
CMP	Target Price
Rs. 91	Rs. 120
EPS change FY12E/13E	(%) (8.5)/(14.6)
Target Price change (%)	(20)
Nifty	5,221
Sensex	17,570

#### **Price Performance**

(%)	1M	3M	6M	12M
Absolute	3	(7)	(41)	(48)
Rel. to Nifty	(5)	(10)	(38)	(38)

Source: Bloomberg

#### **Relative Price Chart**



Source: Bloomberg

## **Stock Details**

Sector	IT Services
Bloomberg	ICSL@IN
Equity Capital (Rs mn)	440
Face Value(Rs)	10
No of shares o/s (mn)	44
52 Week H/L	222/62
Market Cap (Rs bn/USD mn)	4/81
Daily Avg Volume (No of sh)	51631
Daily Avg Turnover (US\$mn)	0.1

# Shareholding Pattern (%)

	Sep-11	Jun-11	Mar-11
Promoters	65.8	64.9	63.8
FII/NRI	15.6	17.3	19.4
Institutions	7.1	7.3	6.8
Private Corp	1.4	1.2	0.9
Public	10.1	9.4	9.1

Source: Capitaline

#### Manik Taneja

manik.taneja@emkayglobal.com +91 22 6612 1253

## Priya Gajwani

priya.gajwani@emkayglobal.com +91 22 6612 1385

- Infinite reported revenues of US\$ 56.2 mn(-4% QoQ), missing expectations driven by ramp down in a key top client. Mgns were flat QoQ (est of +80 bpsQoQ) aided by weak currency
- Pfts at Rs 307 mn bettered est aided by higher other income. Net HC reduced for the 2<sup>nd</sup> qtr in a row(-146 QoQ) with revenues from top 5/10 clients declining by ~7.5/3.2% QoQ
- Co has cut it's US\$ revenue guidance to US\$ 220 mn (+14% YoY) V/s 26.5-29% YoY growth outlook higher on account of rampdowns in a key telecom client account
- Cut FY12/13E EPS by ~8.5/15% to ~Rs 26/28 driven by lower US\$ rev assumptions, albeit aided by lower currency resets. Valuations inexpensive at <4x FY12 P/E. BUY, TP Rs 120</p>

## Disappointing operating performance

Infinite reported a 4% QoQ decline in rev to US\$ 56.2 mn, missing muted expectations of 2.8% QoQ growth. Op mgns were flat seq at 16.9% (V/s est of ~80 bps improvement) aided by lower currency and headcount reduction (Co's headcount reduced for the 2<sup>nd</sup> quarter in a row with utilization increasing to a record high in reporting history). Profits at Rs 307 mn were tad higher than estimates despite op performance miss helped by higher other income ( co reported a Rs 35 mn forex gain V/s expectation of ~Rs 20 mn loss). While top client rev increased by 36% QoQ aided by vendor consolidation gains, revenues from top 5/10 clients were down by ~7.5%/3.2% QoQ impacted adversely by sharp ramp downs in another existing key teleco client (note that this client contributed revenues of ~US\$ 60 mn in FY11), a clearly exposing high client concentration risks for a small/mid size company. DSO increased further to 109 days (V/s 97 days in June'11 qtr) impacted adversely on account of revenue recognition on APDRP.

## New guidance conservative, sharp ramp down in key client worrisome

Infinite's new rev guidance of US\$ 220 mn is very conservative despite the impact of the ramp downs from a key client account as it builds in ~4% sequential decline over the next 2 qtrs. We continue to build in FY12 revenues higher than guidance levels at US\$227 mn, however are negatively surprised by the sharp cuts in business from a key strategic client within the span of 2 quarters and in our view raise doubts about stickiness/annuity nature of business associated typically with IT services business. Discussions with co management indicate that it has seen similar cuts in business from the client in CY06 before a sharp recovery 2-3 quarters later; however a deteriorating macro and risks from vendor consolidation exercises at other major customers will provide little confidence for now.

## Maintain BUY with a revised TP of Rs 120

While we cut our FY12/13 US\$ rev assumptions sharply by 7/11% (we now build in 17/11% YoY growth V/s 26/16% earlier), lower currency resets limit earnings cut to 8.5%/14.6% to Rs 25.9/28 respectively. Valuations at <4x FY12E earnings should limit downsides, with key upsides emerging from positive free cash generation (co has already generated FCF of Rs 280 mn in H1FY12) and new client wins. We retain BUY with a revised TP of Rs 120 (V/s Rs 150 earlier)

## **Financials**

· manoiale										
Y/E March	Net	EBITDA	EBITDA	PAT	EPS	ROE	P/E	EV/	P/B	
(in Rs mn)	Sales		%		(Rs)	%	(x)	EBITDA	(x)	
FY10	6,643	1,214	18.3	792	19.1	35.0	4.8	2.6	1.2	
FY11	8,833	1,479	16.7	1,072	24.4	28.8	3.7	2.3	1.0	
FY12E	10,577	1,770	16.7	1,140	25.9	25.0	3.5	1.7	8.0	
FY13E	12,025	1,999	16.6	1,234	28.0	22.8	3.2	1.3	0.7	

# **Quarterly performance**

Rs mn	Q1FY11	Q2FY11	Q3FY11	Q4 FY11	Q1 FY12	Q2 FY12	YoY (%)	QoQ (%)	YTD 12	YTD 11	YoY (%)
Revenue	1,937	2,194	2,223	2,479	2,623	2,571	17.2	(2.0)	5,195	4,131	25.7
Operating Expenditure	1,619	1,830	1,852	2,053	2,176	2,137	16.8	(1.8)	4,313	3,449	25.0
Cost of revenues	1,444	1,576	1,531	1,512	1,613	1,576	0.0	(2.3)	3,190	3,020	5.6
as % of sales	74.5	71.8	68.9	61.0	61.5	61.3			61.4	73.1	
SG&A expenses	175.2	253.8	321.7	540.4	562.7	561.1	121.1	(0.3)	1,124	429	162.0
as % of sales	9.0	11.6	14.5	21.8	21.5	21.8			21.6	10.4	
EBITDA	318	364	370	426	447	434	19.2	(3.0)	881	682	29.2
Depreciation	29	31	35	72	74	75	138.9	1.1	149	61	145.8
EBIT	289	333	336	354	373	359	7.9	(3.8)	732	621	17.8
Other Income	32	(9)	6	15	27	45			72	23	
PBT	321	324	342	369	400	404	24.8	1.1	804	645	24.7
Total Tax	77	68	72	67	100	97	41.8	(3.6)	197	146	35.3
Adjusted PAT	244	256	271	302	300	307	20.3	2.6	607	499	21.6
(Profit)/loss from JV's/Ass/MI	-	-	-	-	-	-			0	0	
APAT after MI	244	256	271	302	300	307	20.3	2.6	607	499	21.6
Extra ordinary items	0	0	0	0	0	0			0	0	
Reported PAT	244	256	271	302	300	307	20.3	2.6	607	499	21.6
Reported EPS	5.5	5.8	6.2	6.9	6.8	7.0	20.3	2.6	13.8	11.3	21.6

Margins (%)							(bps)	(bps)			(bps)
EBIDTA	16.4	16.6	16.7	17.2	17.0	16.9	29	(17)	17.0	16.5	46
EBIT	14.9	15.2	15.1	14.3	14.2	14.0	(120)	(26)	14.1	15.0	(95)
EBT	16.6	14.8	15.4	14.9	15.2	15.7	96	47	15.5	15.6	(13)
PAT	12.6	11.6	12.2	12.2	11.4	12.0	31	54	11.7	12.1	(39)
Effective Tax rate	24.1	21.1	21.0	18.2	25.1	23.9	286.1	(115.8)	24.5	22.6	192

Source: Company, Emkay Research

In our view, despite the sharp ramp down in business from a key client, company's new revenue guidance is conservative

Revenue (US\$ Mn)	June'11	Sep'11	Dec'11	Mar'12	FY12
Lower End	58.6	56.2	53.8	51.4	220.0
QoQ Growth			-4.1%	-4.3%	-4.3%

Source: Company, Emkay Research

Despite sharp cuts in US\$ revenue assumptions, earnings cut restricted to 8.5%/15% aided by lower currency assumptions

( All fig in Rs mn		FY12E			FY13E	
except EPS)	Old	New	% change	Old	New	% change
Revenues(US\$ mn)	245	227	-7.4	283	251	-11.6
Revenues	11,014	10,577	-4.0	12,757	12,025	-5.7
EBITDA	1,873	1,770	-5.5	2,166	1,999	-7.7
Net profits	1,245	1,140	-8.5	1,446	1,234	-14.6
EPS	28.3	25.9	-8.5	32.9	28.0	-14.6

Source: Company, Emkay Research

Emkay Research 9 November 2011 2

# Operating performance at glance:

	Q2 FY12	Growti	า %
	QZIIIZ	% QoQ	% YoY
Vertical wise split of Revenues			
Telecom & Media	40%	-14%	-21%
Manufacturing	7%	-1%	30%
Healthcare	18%	-3%	14%
Government	10%	-37%	n.a
Retail	6%	1%	72%
Others	18%	98%	128%
Revenue -Service Line Split			
ADM	56%	3%	14%
IP Leveraged/Prod Development	13%	-31%	-29%
Testing	10%	49%	19%
RIM	10%	-55%	40%
Enterprise S/w Solns	2.0%	20%	131%
Revenue-Delivery Split Offshore ,% Onsite	38% 62%	-12% 2%	57% 4%
Revenue-Geographical Split			
US	73%	1%	1%
Europe	6%	17%	44%
India	14%	-34%	179%
APAC	7%	36%	164%
Total Employees	4423	-8%	6%
Client concentration			
Top client	37%	36%	31%
Top 5 clients	75%	-8%	9%
Top 10 clients	93%	-3%	21%
Revenue Engagement Model		bps	bps
T&M	59%	1020	790
Fixed Bid	27%	-650	-626
5 0 1			

14%

-380

-174

Revenue growth impacted adversely by ramp downs in key telecom client

Source: Company, Emkay Research

Revenue Sharing

Emkay Research 9 November 2011 3

# **Financials**

# **Income Statement**

Y/E, Mar (Rs. m)	FY10	FY11	FY12E	FY13E
Net Sales	6,643	8,833	10,577	12,025
Growth (%)		33.0	19.7	13.7
Total Expenditure	(5,430)	(7,354)	(8,807)	(10,026)
Growth (%)		35.4	19.8	13.8
EBIDTA	1,214	1,479	1,770	1,999
Growth (%)		21.9	19.7	13.0
EBIDTA %	18.3	16.7	16.7	16.6
Other Income	(112)	62	63	41
Depreciation	66	167	309	352
EBIT	1,036	1,373	1,523	1,688
Interest	13	17	9	43
EBT	1,024	1,356	1,515	1,645
Tax	232	285	375	411
EAT	792	1,072	1,140	1,234
Growth (%)		35.3	6.4	8.2
EAT (%)	11.9	12.1	10.8	10.3

# **Balance Sheet**

Balarioc Cricci				
Y/E, Mar (Rs. m)	FY10	FY11	FY12E	FY13E
Equity share capital	440	440	440	440
Reserves & surplus	2,830	3,723	4,530	5,403
Minority Interest	-	-	-	-
Networth	3,270	4,163	4,969	5,843
Secured Loans	161	297	608	608
Unsecured Loans	316	164	-	-
Loan Funds	477	461	608	608
Deferred Tax Liabiltiies	64	161	190	190
Total Liabilities	3,810	4,785	5,769	6,641
Goodwill	546	542	542	542
Gross Block	1,133	2,171	2,398	2,878
Less: Depreciation	(320)	(486)	(795)	(1,147)
Net block	1,359	2,227	2,145	2,272
Capital WIP	117	163	163	163
Investment	764	168	474	474
<b>Current Assets</b>	4,165	5,356	6,407	7,472
Inventories	-	-	-	-
Sundry debtors	3,095	3,547	4,086	4,612
Cash & bank balance	548	834	1,133	1,509
Loans & advances	500	950	1,159	1,318
Other current assets	22	25	29	33
Current Liab & Prov	2,731	3,265	3,535	3,855
Current liabilities	2,403	2,931	3,188	3,459
Provisions	328	334	348	395
Net current assets	1,434	2,091	2,872	3,618
Misc exps	-	-	-	-
Deferred Tax Assets	136	135	115	115

## **Cash Flow**

Y/E, Mar (Rs. m)	FY10	FY11	FY12E	FY13E
Net Profit after Tax	792	1,072	1,140	1,234
Add : Depreciation	66	167	309	352
Add: Misc exp w/off	-	7	-	-
Net changes in WC	(452)	(351)	(532)	(417)
<b>Operational Cash Flows</b>	491	973	1,017	1,216
Capital expenditure	(646)	(1,082)	(226)	(480)
Investments	(764)	596	(306)	-
<b>Investing Cash Flows</b>	(1,410)	(486)	(532)	(480)
Borrowings	270	(16)	147	-
dividend paid	-	(154)	(333)	(361)
Issue of shares	955	(29)	(2)	1
Share Premium				
Financing Cash Flows	1,225	(199)	(188)	(360)
changes in cash	305	288	297	376
Opening balance	243	548	834	1,133
Closing balance	548	834	1,133	1,509

## **Key Ratios**

**Total Assets** 

EPS (Rs) 19.1 24.4 25.9 28.0 CEPS (Rs) 20.6 28.2 32.9 36.0 Book Value Per Share (Rs) 74.3 94.6 112.9 132.8 Dividend Per Share (Rs) - 3.0 6.5 7.0 Valuations Ratios (x)  PER 4.8 3.7 3.5 3.2 P/CEPS 4.4 3.2 2.8 2.5 P/BV 1.2 1.0 0.8 0.7 EV/EBIDTA 2.6 2.3 1.7 1.3 EV/Sales 0.5 0.4 0.3 0.2 M-Cap/sales 0.6 0.5 0.4 0.3 0.2 M-Cap/sales 0.6 0.5 0.4 0.3 0.2 EV/EBIDTA 25.0 25.0 RoNW 35.0 28.8 25.0 22.8 EBITDA Margin 18.3 16.7 16.7 16.6 EBIT Margins 17.3 14.8 13.8 13.7	110y Italios				
CEPS (Rs)       20.6       28.2       32.9       36.0         Book Value Per Share (Rs)       74.3       94.6       112.9       132.8         Dividend Per Share (Rs)       -       3.0       6.5       7.0         Valuations Ratios (x)         PER       4.8       3.7       3.5       3.2         P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)       28.8       25.0       22.8         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	Y/E, Mar	FY10	FY11	FY12E	FY13E
Book Value Per Share (Rs)       74.3       94.6       112.9       132.8         Dividend Per Share (Rs)       -       3.0       6.5       7.0         Valuations Ratios (x)       -       3.0       6.5       7.0         PER       4.8       3.7       3.5       3.2         P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	EPS (Rs)	19.1	24.4	25.9	28.0
Dividend Per Share (Rs)       -       3.0       6.5       7.0         Valuations Ratios (x)       -       3.0       6.5       7.0         PER       4.8       3.7       3.5       3.2         P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)       RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	CEPS (Rs)	20.6	28.2	32.9	36.0
Valuations Ratios (x)         PER       4.8       3.7       3.5       3.2         P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	Book Value Per Share (Rs)	74.3	94.6	112.9	132.8
PER       4.8       3.7       3.5       3.2         P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         ROCE       37.5       28.3       26.0       25.0         RONW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	Dividend Per Share (Rs)	-	3.0	6.5	7.0
P/CEPS       4.4       3.2       2.8       2.5         P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	Valuations Ratios (x)				
P/BV       1.2       1.0       0.8       0.7         EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	PER	4.8	3.7	3.5	3.2
EV/EBIDTA       2.6       2.3       1.7       1.3         EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	P/CEPS	4.4	3.2	2.8	2.5
EV/Sales       0.5       0.4       0.3       0.2         M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	P/BV	1.2	1.0	0.8	0.7
M-Cap/sales       0.6       0.5       0.4       0.3         Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	EV/EBIDTA	2.6	2.3	1.7	1.3
Profitability Ratios (%)         RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	EV/Sales	0.5	0.4	0.3	0.2
RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	M-Cap/sales	0.6	0.5	0.4	0.3
RoCE       37.5       28.3       26.0       25.0         RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7					
RoNW       35.0       28.8       25.0       22.8         EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	Profitability Ratios (%)				
EBITDA Margin       18.3       16.7       16.7       16.6         EBIT Margins       17.3       14.8       13.8       13.7	RoCE	37.5	28.3	26.0	25.0
EBIT Margins 17.3 14.8 13.8 13.7	RoNW	35.0	28.8	25.0	22.8
· ·	EBITDA Margin	18.3	16.7	16.7	16.6
	EBIT Margins	17.3	14.8	13.8	13.7
Net Profit Margin 11.9 12.1 10.8 10.3	Net Profit Margin	11.9	12.1	10.8	10.3

3,810

4,785

5,768

6,642

Emkay Research 9 November 2011 4

Infinite Computer Result Update

## Recommendation History: Infinite Computer - ICSL IN

Date	Reports	Reco	СМР	Target
08/08/2011	Infinite Computer Q1FY12 Result Update	Buy	104	160
10/05/2011	Infinite Computer Q4FY11 Result Update	Buy	164	250
02/02/2011	Infinite Computer Q3FY11 Result Update	Buy	181	250
07/12/2010	Infinite Computer Initiating Coverage	Buy	170	250

#### **Recent Research Reports**

Date	Reports	Reco	СМР	Target
31/10/2011	Wipro Q2FY12 Result Update	Reduce	368	360
20/10/2011	Hexaware Technologies Q3CY11 Result Update	Accumulate	89	100
19/10/2011	eClerx Q2FY12 Result Update	Accumulate	732	800
19/10/2011	Patni Computers Q3CY11 Result Update	Not Rated	338	NA

## **Emkay Global Financial Services Ltd.**

Corporate Add: B – Ruby Mills Tower, 7<sup>th</sup> Floor, South East Wing, Senapati Bapat Marg, Dadar (W), Mumbai - 400028 India. Tel.: +912266121212 Web: www.emkayglobal.com

DISCLAIMER: This document is not for public distribution and has been furnished to you solely for your information and may not be reproduced or redistributed to any other person. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries, including the United States. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions. This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. No person associated with Emkay Global Financial Services Ltd. is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this document. The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon. Neither Emkay Global Financial Services Ltd., nor any person connected with it, accepts any liability arising from the use of this document. The recipient of this material should rely on their own investigations and take their own professional advice. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. We and our affiliates, officers, directors, and employees world wide, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities thereof, o

Emkay Research 9 November 2011 www.emkayglobal.com